Pipeline — registered trials by phase
LPP , MP and DP:Relation With Mortality and SOFA in Mechanically Ventilated Patients in ER, Ward and ICU
— · Mechanical Ventilation Complication, Mechanical Power, Driving Pressure · Completed · est. 2020-02-28
Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection
— · Dengue, Dengue Fever, Dengue Fever With Warning Signs · Recruiting · est. 2028-07-31
Prognostic Value of Transcranial Doppler Ultrasound in the Clinical Evolution of Patients With Acute Ischemic Stroke. The TRADE-AIS Study
— · Stroke · Not Yet Recruiting · est. 2027-07-31
Effect of Plant vs Animal Protein Supplementation on Body Composition in Youth Soccer Players
— · Athletic Performance Enhancement, Body Composition Optimization, Nutritional Supplementation in Athletes · Completed · est. 2026-02-18
Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy
— · Procedural Sedation · Completed · est. 2011-10
The Effect of On-line Hemodiafiltratrion on Nutritional Status and Body Composition
— · Chronic Kidney Disease Requiring Chronic Dialysis · Completed · est. 2013-03-31
Effect of KA-EX Supplementation on Recovery Parameters in High-Level Young Football Players
— · Sport, Muscle Fatigue, Recovery of Function (G11.427.698.620) · Not Yet Recruiting · est. 2026-11-05
Educational Intervention to Promote Compression Therapy in People With Venous Ulcer
— · Varicose Ulcer · Recruiting · est. 2025-04-30
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Molina is lead sponsor; 8 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G2026-09-03SCHEDULE 13G
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- SCHEDULE 13G/A2026-08-12SCHEDULE 13G/A
- SCHEDULE 13G/A2026-08-06SCHEDULE 13G/A
- 10-Q2026-07-23Quarterly report
- 8-K2026-07-22Current report (material event)
- 8-K2026-06-10Current report (material event)
- S-82026-05-27Employee stock plan
- SCHEDULE 13G2026-05-14SCHEDULE 13G
- 8-K2026-05-11Current report (material event)
- 8-K2026-05-08Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- 10-Q2026-04-23Quarterly report
- 8-K2026-04-22Current report (material event)
- SCHEDULE 13G/A2026-04-07SCHEDULE 13G/A
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- ARS2026-03-23Annual report to holders
- DEFA14A2026-03-23DEFA14A
- DEF 14A2026-03-23Proxy statement
- PRE 14A2026-03-13PRE 14A
- 8-K2026-02-26Current report (material event)
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-13SCHEDULE 13G/A
- SCHEDULE 13G/A2026-02-12SCHEDULE 13G/A
- 10-K2026-02-10Annual report
- 8-K2026-02-06Current report (material event)
- 8-K2026-02-05Current report (material event)
- SCHEDULE 13G2026-02-05SCHEDULE 13G
- SCHEDULE 13G/A2026-01-21SCHEDULE 13G/A
- 8-K2025-11-20Current report (material event)
- 8-K2025-11-18Current report (material event)
- 8-K2025-11-17Current report (material event)
- 8-K2025-11-14Current report (material event)
- SCHEDULE 13G2025-11-14SCHEDULE 13G
- SCHEDULE 13G2025-11-14SCHEDULE 13G
- 10-Q2025-10-23Quarterly report
- 8-K2025-10-22Current report (material event)
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- SCHEDULE 13G/A2025-08-13SCHEDULE 13G/A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.